Related Experiment Video
Updated: Jun 4, 2025

Isolating Human Peripheral Blood Mononuclear Cells and CD4+ T cells from Sézary Syndrome Patients for Transcriptomic Profiling
Published on: October 14, 2021
A Yale Dermatology perspective on cutaneous T cell lymphoma: Historic reflection to emerging therapies
Madisen A Swallow1, Richard Edelson2, Michael Girardi2
1Yale School of Medicine, New Haven, Connecticut, USA.
Abstract:
Cutaneous T cell lymphoma (CTCL) is a form of non-Hodgkin lymphoma that can involve the skin, along with lymph nodes and blood. The two most common subtypes of CTCL are mycosis fungoides and Sézary syndrome. Since the initial description of mycosis fungoides by Dr Jean-Louis Alibert in 1806, there have been significant advances in our understanding of the pathogenesis of CTCL, its diverse clinical and histologic variants, and the evolving treatment landscape. One major contributor to this story has been Dr Irwin M. Braverman, former vice chair of Dermatology at the Yale School of Medicine. Herein, we provide tribute to his discoveries, teaching, mentorship, and clinical care that have influenced our insights into CTCL and emerging treatments for this challenging malignancy.
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Confocal Fluorescence Microscopy
Targeted Cancer Therapies
There are several types of targeted therapies against...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

